Your browser doesn't support javascript.
Tracking API Quality During a Pandemic
Pharmaceutical Technology Europe ; 32(9):14-17, 2020.
Article in English | ProQuest Central | ID: covidwho-20233951
ABSTRACT
With additional safety protocols required in the manufacturing environment, gatherings of large people generally prohibited, and onsite inspections limited due to restricted travel, ensuring quality throughout the supply chain from raw material to API is more challenging. Employee safety is always a priority for Thermo Fisher Scientific, and since the start of the COVID-19 pandemic the company has focused on protecting their health and safety while continuing to serve the needs of its customers, according to Vice President of Drug Substance Quality, Ben Gerlach. [...]of the support, flexibility, and discipline of our colleagues and supply chain partners, as well as the IT infrastructure available, all Thermo Fisher API manufacturing sites have remained operational since the start of the pandemic with continued GMP compliance," Gerlach remarks. Expanding our footprint and ensuring supply chain redundancy has enabled us to minimize the risk of supply chain interruptions and work with partners efficiently," he explains. Because of the circumstances connected with COVID-19, Ross also stresses that it is extremely important to frequently engage with supply chain partners to ensure that Cambrex understands the impact of the pandemic on their businesses and any potential downstream effects on Cambrex's unit operations that might ensue.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Pharmaceutical Technology Europe Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Pharmaceutical Technology Europe Year: 2020 Document Type: Article